A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Pegadricase (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
- 12 Sep 2018 Planned End Date changed from 31 Dec 2018 to 31 Jan 2020.
- 12 Sep 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jul 2019.
- 05 Jan 2018 New trial record